Status:
COMPLETED
Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of PF-04236921 administered as a single subcutaneous dose in healthy volunteers.
Detailed Description
Tolerability and Pharmacokinetics of subcutaneously administered dose of PF-04236921 in healthy volunteers
Eligibility Criteria
Inclusion
- Healthy males between 18-55 years, inclusive.
- Healthy females of non-childbearing potential between 18 and 55 years, inclusive.
Exclusion
- Evidence or history of clinically significant disease.
- Females of childbearing potential.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01166555
Start Date
May 1 2010
End Date
October 1 2010
Last Update
November 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1070